Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding
The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). Thes...
Gespeichert in:
Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2015-03, Vol.61 (3), p.1024-1032 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1032 |
---|---|
container_issue | 3 |
container_start_page | 1024 |
container_title | Hepatology (Baltimore, Md.) |
container_volume | 61 |
creator | Thabut, Dominique Rudler, Marika Dib, Nina Carbonell, Nicolas Mathurin, Philippe Saliba, Faouzi Mallet, Alain Massard, Julien Bernard‐Chabert, Brigitte Oberti, Frederic Cales, Paul Golmard, Jean‐Louis Bureau, Christophe |
description | The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted‐blood‐requirement‐index (ABRI = number of blood units/(final‐initial hematocrit + 0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5‐day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c‐statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P = 0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024–1032) |
doi_str_mv | 10.1002/hep.27407 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01392302v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1658420681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4207-4d3d73f4fdd072afdc1c3eb7dd8dabe7f6c5df0a6179c373f1715ae6e81873223</originalsourceid><addsrcrecordid>eNqNkU1P3DAQhq2qqGyhh_6BylIv7SGsP5LYOQICNtIiOECvlteeNEbeJLWTRah_Hi9Lt1KlSpwsW888npkXoc-UnFBC2LyF4YSJnIh3aEYLJjLOC_IezQgTJKsorw7RxxgfCCFVzuQHdMgKKipayhn6fT350RnoRgh4CH0cwIxuA3ijvbN6dH2H-waPLeAzvYGux_UPrDu7v9Xzuq6xCS4JnMauw8aF0PbRRTyk-mSO-NGNbTKG9JH2eOUBrOt-HqODRvsIn17PI3R_eXF3vsiWN1f1-ekyMzkjIsstt4I3eWMtEUw31lDDYSWslVavQDSlKWxDdJlmMjyRVNBCQwmSSsEZ40fo-87baq-G4NY6PKleO7U4XartG0krYpywDU3stx2bdvFrgjiqtYsGvNcd9FNUtCxTU5JVb0ELmdhSbtGv_6AP_RS6NPSWEryglZB_-zQphxig2TdLidoGrVLQ6iXoxH55NU6rNdg9-SfZBMx3wKPz8PR_k1pc3O6UzwgIsU8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1657351978</pqid></control><display><type>article</type><title>Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Thabut, Dominique ; Rudler, Marika ; Dib, Nina ; Carbonell, Nicolas ; Mathurin, Philippe ; Saliba, Faouzi ; Mallet, Alain ; Massard, Julien ; Bernard‐Chabert, Brigitte ; Oberti, Frederic ; Cales, Paul ; Golmard, Jean‐Louis ; Bureau, Christophe</creator><creatorcontrib>Thabut, Dominique ; Rudler, Marika ; Dib, Nina ; Carbonell, Nicolas ; Mathurin, Philippe ; Saliba, Faouzi ; Mallet, Alain ; Massard, Julien ; Bernard‐Chabert, Brigitte ; Oberti, Frederic ; Cales, Paul ; Golmard, Jean‐Louis ; Bureau, Christophe ; French Club for the Study of Portal Hypertension (CFEHTP) ; for the French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><description>The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted‐blood‐requirement‐index (ABRI = number of blood units/(final‐initial hematocrit + 0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5‐day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c‐statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P = 0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024–1032)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.27407</identifier><identifier>PMID: 25179168</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Blood Transfusion ; Esophageal and Gastric Varices - diagnosis ; Esophageal and Gastric Varices - mortality ; Esophageal and Gastric Varices - therapy ; Gastrointestinal Hemorrhage - diagnosis ; Gastrointestinal Hemorrhage - mortality ; Gastrointestinal Hemorrhage - therapy ; Hepatology ; Humans ; Life Sciences ; Liver Cirrhosis - complications ; Prospective Studies ; Treatment Failure</subject><ispartof>Hepatology (Baltimore, Md.), 2015-03, Vol.61 (3), p.1024-1032</ispartof><rights>2014 by the American Association for the Study of Liver Diseases</rights><rights>2014 by the American Association for the Study of Liver Diseases.</rights><rights>2015 by the American Association for the Study of Liver Diseases</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4207-4d3d73f4fdd072afdc1c3eb7dd8dabe7f6c5df0a6179c373f1715ae6e81873223</citedby><cites>FETCH-LOGICAL-c4207-4d3d73f4fdd072afdc1c3eb7dd8dabe7f6c5df0a6179c373f1715ae6e81873223</cites><orcidid>0000-0003-3447-2025 ; 0000-0003-4866-5274</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.27407$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.27407$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25179168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01392302$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Thabut, Dominique</creatorcontrib><creatorcontrib>Rudler, Marika</creatorcontrib><creatorcontrib>Dib, Nina</creatorcontrib><creatorcontrib>Carbonell, Nicolas</creatorcontrib><creatorcontrib>Mathurin, Philippe</creatorcontrib><creatorcontrib>Saliba, Faouzi</creatorcontrib><creatorcontrib>Mallet, Alain</creatorcontrib><creatorcontrib>Massard, Julien</creatorcontrib><creatorcontrib>Bernard‐Chabert, Brigitte</creatorcontrib><creatorcontrib>Oberti, Frederic</creatorcontrib><creatorcontrib>Cales, Paul</creatorcontrib><creatorcontrib>Golmard, Jean‐Louis</creatorcontrib><creatorcontrib>Bureau, Christophe</creatorcontrib><creatorcontrib>French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><creatorcontrib>for the French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><title>Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted‐blood‐requirement‐index (ABRI = number of blood units/(final‐initial hematocrit + 0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5‐day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c‐statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P = 0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024–1032)</description><subject>Blood Transfusion</subject><subject>Esophageal and Gastric Varices - diagnosis</subject><subject>Esophageal and Gastric Varices - mortality</subject><subject>Esophageal and Gastric Varices - therapy</subject><subject>Gastrointestinal Hemorrhage - diagnosis</subject><subject>Gastrointestinal Hemorrhage - mortality</subject><subject>Gastrointestinal Hemorrhage - therapy</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Liver Cirrhosis - complications</subject><subject>Prospective Studies</subject><subject>Treatment Failure</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1P3DAQhq2qqGyhh_6BylIv7SGsP5LYOQICNtIiOECvlteeNEbeJLWTRah_Hi9Lt1KlSpwsW888npkXoc-UnFBC2LyF4YSJnIh3aEYLJjLOC_IezQgTJKsorw7RxxgfCCFVzuQHdMgKKipayhn6fT350RnoRgh4CH0cwIxuA3ijvbN6dH2H-waPLeAzvYGux_UPrDu7v9Xzuq6xCS4JnMauw8aF0PbRRTyk-mSO-NGNbTKG9JH2eOUBrOt-HqODRvsIn17PI3R_eXF3vsiWN1f1-ekyMzkjIsstt4I3eWMtEUw31lDDYSWslVavQDSlKWxDdJlmMjyRVNBCQwmSSsEZ40fo-87baq-G4NY6PKleO7U4XartG0krYpywDU3stx2bdvFrgjiqtYsGvNcd9FNUtCxTU5JVb0ELmdhSbtGv_6AP_RS6NPSWEryglZB_-zQphxig2TdLidoGrVLQ6iXoxH55NU6rNdg9-SfZBMx3wKPz8PR_k1pc3O6UzwgIsU8</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Thabut, Dominique</creator><creator>Rudler, Marika</creator><creator>Dib, Nina</creator><creator>Carbonell, Nicolas</creator><creator>Mathurin, Philippe</creator><creator>Saliba, Faouzi</creator><creator>Mallet, Alain</creator><creator>Massard, Julien</creator><creator>Bernard‐Chabert, Brigitte</creator><creator>Oberti, Frederic</creator><creator>Cales, Paul</creator><creator>Golmard, Jean‐Louis</creator><creator>Bureau, Christophe</creator><general>Wolters Kluwer Health, Inc</general><general>Wiley-Blackwell</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-3447-2025</orcidid><orcidid>https://orcid.org/0000-0003-4866-5274</orcidid></search><sort><creationdate>201503</creationdate><title>Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding</title><author>Thabut, Dominique ; Rudler, Marika ; Dib, Nina ; Carbonell, Nicolas ; Mathurin, Philippe ; Saliba, Faouzi ; Mallet, Alain ; Massard, Julien ; Bernard‐Chabert, Brigitte ; Oberti, Frederic ; Cales, Paul ; Golmard, Jean‐Louis ; Bureau, Christophe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4207-4d3d73f4fdd072afdc1c3eb7dd8dabe7f6c5df0a6179c373f1715ae6e81873223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Blood Transfusion</topic><topic>Esophageal and Gastric Varices - diagnosis</topic><topic>Esophageal and Gastric Varices - mortality</topic><topic>Esophageal and Gastric Varices - therapy</topic><topic>Gastrointestinal Hemorrhage - diagnosis</topic><topic>Gastrointestinal Hemorrhage - mortality</topic><topic>Gastrointestinal Hemorrhage - therapy</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Liver Cirrhosis - complications</topic><topic>Prospective Studies</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thabut, Dominique</creatorcontrib><creatorcontrib>Rudler, Marika</creatorcontrib><creatorcontrib>Dib, Nina</creatorcontrib><creatorcontrib>Carbonell, Nicolas</creatorcontrib><creatorcontrib>Mathurin, Philippe</creatorcontrib><creatorcontrib>Saliba, Faouzi</creatorcontrib><creatorcontrib>Mallet, Alain</creatorcontrib><creatorcontrib>Massard, Julien</creatorcontrib><creatorcontrib>Bernard‐Chabert, Brigitte</creatorcontrib><creatorcontrib>Oberti, Frederic</creatorcontrib><creatorcontrib>Cales, Paul</creatorcontrib><creatorcontrib>Golmard, Jean‐Louis</creatorcontrib><creatorcontrib>Bureau, Christophe</creatorcontrib><creatorcontrib>French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><creatorcontrib>for the French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thabut, Dominique</au><au>Rudler, Marika</au><au>Dib, Nina</au><au>Carbonell, Nicolas</au><au>Mathurin, Philippe</au><au>Saliba, Faouzi</au><au>Mallet, Alain</au><au>Massard, Julien</au><au>Bernard‐Chabert, Brigitte</au><au>Oberti, Frederic</au><au>Cales, Paul</au><au>Golmard, Jean‐Louis</au><au>Bureau, Christophe</au><aucorp>French Club for the Study of Portal Hypertension (CFEHTP)</aucorp><aucorp>for the French Club for the Study of Portal Hypertension (CFEHTP)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2015-03</date><risdate>2015</risdate><volume>61</volume><issue>3</issue><spage>1024</spage><epage>1032</epage><pages>1024-1032</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted‐blood‐requirement‐index (ABRI = number of blood units/(final‐initial hematocrit + 0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5‐day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c‐statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P = 0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024–1032)</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>25179168</pmid><doi>10.1002/hep.27407</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3447-2025</orcidid><orcidid>https://orcid.org/0000-0003-4866-5274</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-9139 |
ispartof | Hepatology (Baltimore, Md.), 2015-03, Vol.61 (3), p.1024-1032 |
issn | 0270-9139 1527-3350 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_01392302v1 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Blood Transfusion Esophageal and Gastric Varices - diagnosis Esophageal and Gastric Varices - mortality Esophageal and Gastric Varices - therapy Gastrointestinal Hemorrhage - diagnosis Gastrointestinal Hemorrhage - mortality Gastrointestinal Hemorrhage - therapy Hepatology Humans Life Sciences Liver Cirrhosis - complications Prospective Studies Treatment Failure |
title | Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A58%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20prospective%20validation%20of%20the%20Baveno%20IV%20and%20Baveno%20II/III%20criteria%20in%20cirrhosis%20patients%20with%20variceal%20bleeding&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Thabut,%20Dominique&rft.aucorp=French%20Club%20for%20the%20Study%20of%20Portal%20Hypertension%20(CFEHTP)&rft.date=2015-03&rft.volume=61&rft.issue=3&rft.spage=1024&rft.epage=1032&rft.pages=1024-1032&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.27407&rft_dat=%3Cproquest_hal_p%3E1658420681%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1657351978&rft_id=info:pmid/25179168&rfr_iscdi=true |